Overview

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2023-11-10
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety/tolerability, pharmacokinetics, and preliminary efficacy of GFH018 in combination with Toripalimab in patients with advanced solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Zhejiang Genfleet Therapeutics Co., Ltd.